期刊文献+

齐拉西酮替换氯氮平治疗精神分裂症50例临床观察

Clinical Eiffcacy Study on Ziprasidone Alternated to Clozapine for 50 Schizophrenia Patients
下载PDF
导出
摘要 目的观察齐拉西酮替换氯氮平治疗精神分裂症的临床疗效及不良反应。方法选取我院50例既往服用氯氮平的精神分裂症患者替换为齐拉西酮治疗16周。分别于服齐拉西酮前及服药后2,4,6,8,12,16周末采用简明精神病评定量表(BPRS)评定疗效,服药第16周末采用副反应量表(TESS)评定不良反应。结果患者治疗后6,8,12,16周简明精神病评定量表总分较治疗前显著下降(P<0.05或0.01)。其中45例患者成功替换为单剂齐拉西酮治疗。结论齐拉西酮代替氯氮平治疗精神分裂症疗效肯定,不良反应较少,患者的认知功能得到改善,服药依从性升高。 Objective To explore the efficacy and side effect of Ziprasidone substitutes chlorine nitrogen for schizophrenia patients.Methods A total of 50 patients with schizophrenia took medicines from Clozapine to Ziprasidone 16 weeks,Adoption Brief Psychiatric Rating Scaleb and Treatment Emergent Symptom Scale to assess efficacy and bad reaction respectively before taking Ziprasidone and 2,4 ws,6 ws and 8 ws,12 ws and 16 w end and in 16 w end to adopt the Treatment Emergent Symptom Scale(TESS) to assess side effect.Results The scores of BPRS in 6 ws,the 8 ws,12 ws and 16 w aftertreatment were significantly lower than before tredtment(P0.05 or 0.01)45 among the sufferers successfully substituted for the list to Ziprasidone treatment.Conclusion Ziprasidone has a good efficacy and low side effect,it can improve cognition function and compliance.
作者 封正敏
出处 《中国健康心理学杂志》 2011年第10期1187-1188,共2页 China Journal of Health Psychology
关键词 齐拉西酮 氯氮平 精神分裂症 简明精神病评定量表 Ziprasidone Chlorine Schizophrenia BPRS
  • 相关文献

参考文献6

二级参考文献31

  • 1刘燕,李华芳,王慧芳,王克勋,高哲石,顾牛范.氯氮平、利培酮对精神分裂症病人血糖-胰岛素稳态的影响及相关因素分析[J].上海精神医学,2003,15(5):257-259. 被引量:33
  • 2陈俊,王红星,徐鹤定,王祖承,方贻儒.2005年住院精神疾病患者药物治疗时点调查[J].临床精神医学杂志,2006,16(4):197-198. 被引量:37
  • 3Harvey PD, Bowie CR. Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness [J].Expert Opin Pharmacother,2005,6(2): 337
  • 4Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia [ J]. Prog Neuropsychopharmacol Biol Psychiatry, 2005,29 (2) : 219
  • 5STAHI SM, SHAYEGAN DK. The psychopharmacology of ziprasidone: receptor-binding propreties and real-world psychiatric practice[J]. J Clin Psychiatry, 2003,64 Suppl 19 : 6-12.
  • 6CALEY CF, COOPER CK. Ziprasidone: the fifth atypical antipsychotie[J]. Ann Pharmaeother. 2002, 36(5 ) : 839-851.
  • 7KANE JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials[J]. J Clin Psychiatry, 2003, 64 Suppl 19:19-25.
  • 8HARVEY PD, SIU CO, ROMANO S. Randomized, controlled,double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder[J]. Psychopharmacology, 2004, 172(3) :324-332.
  • 9HIRSCH SR, KISSLING W, BAUML J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia[J]. J Clin Psychiatry, 2002, 63 (6) : 516-523.
  • 10NEMEROFF CB, LIEBERMAN JA, WEIDEN PJ, et al. From clinical research to clinical practive: a d-year review of ziprasidone[J]. CNS Spectr, 2005, 10( 11 ) :s1-s20.

共引文献3093

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部